| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 436071000 | LIPIDS, TRIGLYCERIDES, CHOLESTEROL, OR LIPOPROTEINS | 77 |
| 20080227209 | Methods, Kits And Devices For Analysis Of Lipoprotein(a) - Methods for optically detecting lipoproteins, in particular lipoprotein(a), in a sample. In some embodiments, the methods include contacting a sample with an associative lipophilic dye, subjecting the sample to electrophoretic separation through a separation medium, and detecting the dye. Kits comprising microchips for performing a separation of lipoproteins, including lipoprotein(a), are also provided. | 09-18-2008 |
| 20080241942 | AIR-STABLE SUPPORTED LIPID BILAYER MEMBRANES - The present invention relates to methods for fabricating air-stable supported lipid bilayer membranes. In one embodiment, the present invention relates to methods of producing supported lipid bilayer membranes stabilized by sterol groups that are covalently tethered to a solid surface. In a further embodiment, the present invention relates to air-stable supported lipid bilayer membranes produced by the methods of the present invention. | 10-02-2008 |
| 20080274555 | Separation and Manipulation of a Chiral Object - Among other things, for use in directional motion of chiral objects in a mixture, a field is applied across the chamber and is rotating relative to the chamber to cause rotation of the chiral objects. The rotation of the objects causes them to move directionally based on their chirality. The method applies to sugars, proteins, and peptides, among other things, and can be used in a wide variety of applications. | 11-06-2008 |
| 20080305549 | LIPOPROTEIN ANALYSIS BY DIFFERENTIAL CHARGED-PARTICLE MOBILITY - The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention. | 12-11-2008 |
| 20080305550 | Targets for Detection of Ischemia - The subject application comprises methods for determining the occurrence of an ischemic event in a subject by determining an ischemia score based on the amount of at least two ischemia modified albumin markers. The ischemia modified albumin markers include complexes of fatty acids bound to albumin, albumin molecules with open Cys34 sites, albumin molecules that are products of oxidation at Cys34, albumin molecules with altered conformation or altered divalent metal binding due to the conformational change or oxidation at Cys34, and albumin molecules that have been oxidized at the N-terminus. Also included in the invention are ligands to each of the foregoing ischemia modified albumin markers. Further included are methods of determining the occurrence of an ischemic event by determining the amount of fatty acid that is complexed to albumin in a patient sample. In another embodiment, an ischemic event is determined by quantitating the relative amounts of reduced and oxidized forms of albumin Cys34. In an additional embodiment, an ischemic event is determined by observing whether a shift in albumin conformation has occurred which would reflect oxidized Cys34. Further, the invention comprises a method of determining an ischemic event by determining the amount of metal ion bound to the albumin metal ion binding sites. | 12-11-2008 |
| 20080311667 | Exogenous Markers for Oxidative Stress - The invention provides oxogenous markers, designed and synthesized for the measurement and characterization of oxidative/nitrosative stress levels, thus enable the identification of the type of reactive ROS/NRS involved, characterization of the damaged products and their formation kinetics, and thereby the identification of pathological conditions associated with oxidative/nitrosative stress, before appearing or at the stage of development. | 12-18-2008 |
| 20080318325 | Method for the Analysis of Liposomes - A method for the determination of the morphological integrity of a membrane of lipid vesicles, such as liposomes, using electron spin resonance (ESR) spectroscopy including the steps of: a) labeling the lipid vesicles with an ESR-active probe; b) producing a sample by introducing a quantity of the labeled lipid vesicles into a test medium; c) producing a positive control by introducing a quantity of the labeled lipid vesicles into a control medium and optionally a negative control by introducing a quantity of the ESR-active probe into the test medium; d) obtaining ESR spectra of the controls and the sample; and e) comparing ESR spectra of the sample and controls to determine relative morphological integrity. Morphological integrity of lipid vesicles may be quantitatively determined in the test medium by obtaining difference spectra produced using the spectra of the sample and of the positive and/or negative control. | 12-25-2008 |
| 20090081796 | METHOD FOR THE DETERMINATION OF PHOSPHOLIPIDS IN AMNIOTIC FLUID SAMPLES - The present invention refers to a fast method for the determination of phospholipids in amniotic fluid samples by HPTLC (high performance thin layer chromatography). This innovative method presents high sensitivity, reproducibility and resolution. It has also the advantage of being of easy laboratorial interpretation, allowing the elimination of false results due to the contamination of the sample with blood or meconium. | 03-26-2009 |
| 20090117661 | METHOD OF ELIMINATING REACTIVITY OF LIPOARABINOMANNAN AND APPLICATION OF THE SAME - A method of eliminating the reactivity of lipoarabinomannan contained in a sample to a | 05-07-2009 |
| 20090155915 | Biological markers for longevity and diseases and uses thereof - This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the -641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease. | 06-18-2009 |
| 20090221081 | METABOLITE MARKERS FOR WEIGHT MANAGEMENT - The present invention provides methods of using certain metabolite markers for predicting weight development or its related conditions of a subject. The present invention also provides compositions and kits useful for detecting metabolite markers of the present invention. | 09-03-2009 |
| 20090246878 | METHOD AND APPARATUS FOR ANALYZING VITAMIN E IN LIPOPROTEINS - A method of analyzing vitamin E components in a lipoprotein, which comprises subjecting a lipoprotein-containing sample to ion exchange chromatography to separate the lipoprotein, reacting the separated lipoprotein to a pretreating solution containing an organic solvent and a surfactant to liberate vitamin E components, and then subjecting the liberated vitamin E components to reverse phase chromatography, and a method of judging various pathological conditions such as the pathological conditions of diabetes, the risks of coronary artery diseases, and the pathological conditions of myocardial infarction using levels of vitamin E components in the lipoprotein as an index. | 10-01-2009 |
| 20090263906 | METHOD OF ANTIOXIDATIVE FUNCTIONAL ESTIMATION USING ANIMAL MODEL - The present invention relates to a method of antioxidative functional estimation using an animal model, more precisely a method of antioxidative functional estimation using mice having oxidative damage caused by reactive oxygen species induced by irradiation and having lipid hydroperoxide secreted in the urine which might be index for quantitative and qualitative analysis for antioxidative functional estimation. The method of antioxidative functional estimation of the present invention can be effectively used for the screening of a novel anti-oxidant agent or antioxidative functional health food to regulate the production of lipid hydroperoxide. | 10-22-2009 |
| 20100003761 | METHODS FOR THE DIAGNOSIS OF DEMENTIA AND OTHER NEUROLOGICAL DISORDERS - The present invention is directed to a method for differentially diagnosing dementia or the risk of dementia in a patient. The method comprises obtaining a sample from the patient; analyzing the sample to obtain quantifying data for one or more than one metabolite marker; comparing the quantifying data for the one or more than one metabolite marker to corresponding data obtained from one or more than one reference sample; and using the comparison to differentially diagnose dementia or the risk of dementia. The method may also assis in assessing dementia or the risk of dementia in a patient. The present invention is also directed to metabolite markers and compounds useful in the present method. | 01-07-2010 |
| 20100055796 | ESTIMATION AND BIOLOGICAL CONSEQUENCES OF OXIDATIVE METABOLISM - The present invention relates to monitoring of oxidative metabolism and is, particularly, directed to a method for the estimation of lipid peroxide load or the consequent inflammatory state of a subject by measuring the concentration of oxidized HDL lipids of said subject. In addition, the invention is also directed to methods for elimination of lipid peroxidation products, and attenuation of the resulting oxidative stress and inflammatory state in human body, by increasing the lipid peroxide transporting capacity of HDL. | 03-04-2010 |
| 20100093100 | PROFILING METHOD USEFUL FOR CONDITION DIAGNOSIS AND MONITORING, COMPOSITION SCREENING, AND THERAPEUTIC MONITORING - The presently-disclosed subject matter includes methods and systems for identifying biomarkers of interest, diagnosing and/or monitoring conditions of interest, assessing the efficacy of a treatment program, and composition screening. Exemplary methods include providing a sample of interest, fractionating the sample, generating thermograms, and comparing thermograms. | 04-15-2010 |
| 20100197029 | DIRECT METHOD AND REAGENT KITS FOR FATTY ACID ESTER SYNTHESIS - Provided are efficient, cost-effective and water tolerant methods (e.g., single-vial methods) for preparing fatty acid esters from organic matter, comprising: obtaining organic matter comprising at least one fat substituent, contacting the organic matter in a reaction mixture with a basic solution under conditions suitable to provide for hydrolytic release of monomeric fatty acids from the at least one fat substituent to provide a base-treated reaction mixture, and esterifying the monomeric fatty acids of the base-treated reaction mixture by acidification of the reaction mixture and treating in the presence of an organic alcohol to provide fatty acid esters. The methods optionally further comprise, prior to esterifying, neutralizing the base-treated reaction mixture to provide for neutralized fatty acids, separating the neutralized fatty acids from the neutralized reaction mixture, and dissolving the separated fatty acids in the esterification reaction mixture. Also provided are related methods and kits for fat analysis. | 08-05-2010 |
| 20100248375 | METHOD FOR PREDICTING RESPONSIVENESS TO A PHARMACEUTICAL THERAPY FOR OBESITY - Methods for using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by a weight loss pharmaceutical agent. The biomarker may be used for determining if an individual patient will likely respond favorably to a given weight loss pharmaceutical agent. | 09-30-2010 |
| 20100261281 | ANALYTICAL TECHNIQUE FOR MEASURING BOUND GLYCERIDES IN A BIODIESEL COMPOSITION - A method of estimating the amount of unreacted starting materials (glycerides, methyl esters, etc.) and the composition of a biodiesel using TLC in conjunction with a lipophilic dye, Nile Red is described herein. The dye based TLC method of the present invention is convenient and provides significant advantages over existing methods for estimating the purity of a biodiesel composition. | 10-14-2010 |
| 20100267148 | METHOD FOR THE DETERMINATION OF THE POSITION OF UNSATURATION IN A COMPOUND - A mass spectrometric method for determining the position of unsaturation in a compound is disclosed. | 10-21-2010 |
| 20100285596 | METHODS FOR ISOLATING FUNCTIONALIZED MACROMOLECULES - The invention provides methods of isolating, purifying, analyzing and/or detecting, functionalized macromolecules, e.g., peptides, phosphopeptides, polypeptides, proteins, oligonucleotides, or phospholipids in a sample, e.g., a biological mixture, using solid phase extraction with an alumina sorbent packed in a micro-elution plate. | 11-11-2010 |
| 20100311175 | MASS TAGS FOR QUANTITATIVE ANALYSES - This invention pertains to methods, mixtures, kits and/or compositions for the determination of analytes by mass analysis using unique labeling reagents or sets of unique labeling reagents. The labeling reagents can be isomeric or isobaric and can be used to produce mixtures suitable for multiplex analysis of the labeled analytes. | 12-09-2010 |
| 20100323451 | METHOD OF PREDICTING PHOSPOLIPIDOSIS INDUCING PROPERTIES OF A SUBSTANCE - The present invention is directed to a method for predicting the risk of a substance exhibiting phospholipidosis inducing properties, the method comprising adding the said substance to an anionic surfactant to form a mixture of said substance and said surfactant, and determining the effect of said substance on the critical micelle concentration (CMC) of the anionic surfactant by determining the CMC of the mixture, whereby a decrease in the CMC as compared to the CMC of the surfactant prior to the addition of the substance is indicative of a risk of said substance exhibiting phospholipidosis inducing properties. | 12-23-2010 |
| 20110020942 | MEASURING LEVELS OF A METABOLITE - Described herein are methods for determining an amount of an analyte in a test sample. The methods involve preparing a calibration curve using standard samples containing an isotopically-labeled standard in a biological matrix. | 01-27-2011 |
| 20110033939 | METHOD OF MEASURING LIPOARABINOMANNAN AND APPLICATION THEREOF - A method for measuring LAM and a method for detecting an acid-fast bacterium, which comprise at least a step of allowing a | 02-10-2011 |
| 20110059533 | FLUORESCENCE DETECTION SYSTEM, METHOD, AND DEVICE FOR MEASURING BIOMOLECULES - A fluorescence detection system for measuring biomolecules is disclosed, which includes a fluorescence detection device, a light source, a sample-loading unit, and an analysis-reading device. The fluorescence detection device has a substrate and plural phototransistors arranged on the substrate, and each phototransistor contains an emitter, a collector locating on the substrate, and a base between the emitter and the collector. The base-collector diode junction functions as an absorber to convert fluorescence to photocurrent. The light source serves to excite a fluorescent dye contained in a biomolecule sample. The sample-loading unit is used to load or transport the excited biomolecule sample onto a sensing zone of the fluorescence detection device. The analysis-reading device is to measure photocurrent output from the fluorescence detection device under a bias. Hence, the biomolecule content can be easily determined by the fluorescence detection system. | 03-10-2011 |
| 20110059534 | DETERMINATION OF TESTOSTERONE BY MASS SPECTROMETRY - Provided are methods for determining the presence or amount of testosterone in a test sample, comprising ionizing all or a portion of the testosterone present in the sample to produce one or more testosterone ions that are detectable in a mass spectrometer. All or a portion of the testosterone present in the sample is ionized to produce one or more testosterone ions, which may be isolated and fragmented to produce precursor ions. A separately detectable internal testosterone standard can be provided in the sample. In a preferred embodiment, the reference is 2,2,4,6,6-d | 03-10-2011 |
| 20110065194 | Microfluidic detection device and method for detecting molecules using the same - A microfluidic detection device is disclosed, which includes a porous membrane, a wicking pad, and an optical sensor. The porous membrane has a first end and an opposite second end, and the first end has a sample-loading area for receiving sample molecules. The wicking pad is connected with the second end of the porous membrane to move the sample molecules from the sample-loading area of the porous membrane to the second end thereof. The optical sensor has a detection zone which faces the porous membrane for sensing the sample molecules. Also, a method for detecting molecules is disclosed, which uses the aforesaid device. The method and the device can achieve the purpose of real-time detection and fast-screening for molecules. | 03-17-2011 |
| 20110076775 | METHODS, SYSTEMS AND DEVICES FOR ANALYZING A SURFACTANT-TREATED BIOLOGICAL FLUID SAMPLE - Devices, methods and systems effective to evaluate a physical or chemical property of a surfactant-treated biological fluid sample are provided. | 03-31-2011 |
| 20110076776 | METHODS, SYSTEM AND DEVICES FOR ANALYZING A BIOLOGICAL FLUID SAMPLE FOLLOWING ION EXCHANGE - Devices, methods and systems effective to evaluate a physical or chemical property of an ion exchange resin-treated biological fluid sample are provided. | 03-31-2011 |
| 20110111511 | METHODS FOR MEASURING THE METABOLISM OF NEURALLY DERIVED BIOMOLECULES IN VIVO - The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided. | 05-12-2011 |
| 20110129932 | Lipoprotein Assay - The present invention concerns a method of determining the concentration of total lipoprotein in a sample. The method involves the steps of: (i) adding to an aliquot of the sample a lipophilic dye that binds to lipoproteins in the sample and which when so bound fluoresces under appropriate excitation; and (ii) determining the total lipoprotein concentration in the sample using fluorescence analysis. A method of analysing the lipoprotein content of a sample solution using a dye that discriminates between different types of lipoprotein is also disclosed. | 06-02-2011 |
| 20110129933 | MEANS AND METHODS FOR ASSESSING INCREASED PEROXISOMAL PROLIFERATION - The present invention pertains to the field of toxicological as for risk stratification of chemical compounds. Specifically, it relates to methods for (i) diagnosing, (ii) determining whether a compound is capable of inducing, (iii) identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosis. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of diagnostic devices or compositions. The metabolite markers of the metabolome are selected from: Coenzyme Q10, 16-Methylheptadecanoic acid, 17-Methyloctadecanoic acid, Eicosatrienoic acid (C20:3), Threonine, Proline, Tyrosine, trans-4-Hydroxyprolme, Pantothenic acid, Coenzyme Q9, Glycerol, Palmitic acid (C16:0), Lmoleic acid (C18:cis (9, 12) 2), 14-Methylhexadecanoic acid, gamma-Linoleic acid (C18:cis (6, 9, 12) 3), Threonic acid, Cytosine, Phosphatidyl-choline (C18:0/C22:6). Different multimarker sets are proposed for male and female subjects. | 06-02-2011 |
| 20110136242 | Lanthanide Chelates and Use Thereof in Bioanalysis - Novel chemical compounds, with application in fluorometric analytical methods, for qualitative and quantitative determination of biomolecules. The aim of the invention is to identify and prove the suitability of such compounds. Said aim is achieved with compounds of formula (1) where R′ is an antenna function, R | 06-09-2011 |
| 20110136243 | HIGH THROUGHPUT METHOD FOR ANALYZING THE FATTY ACID COMPOSITION IN PLASMA PHOSPHOGLYCERIDES - A method is described for determining the fatty acid composition of phosphoglycerides. In said method, methanol is added to a sample containing phosphoglycerides, the combination is mixed, precipitated material is separated from the methanol phase, an alkali alkoxide is added to the methanol phase as a base in order to catalyze a transesterification process, and the produced methyl esters are extracted from the solution obtained following the transesterification process and are gas-chromatographically separated. A test kit that is suitable for carrying out said method is also disclosed. | 06-09-2011 |
| 20110207230 | EVALUATION OF 24S-HYDROXYCHOLESTEROL IN HAIR FOR METABOLIC BIOMARKER OF ALZHEIMER'S DISEASE - Disclosed is a method for detection of 24S-hydroxycholesterol in hair. More specifically, a trace amount of hair is hydrolyzed under basic condition and metabolites including 24S-hydroxycholesterol are purified and extracted by solid-phase extraction (SPE). Then, after derivatization of the resulting extract with trimethylsilyl (TMS), 24S-hydroxycholesterol is detected by gas chromatography-mass spectrometry (GC-MS). | 08-25-2011 |
| 20110223675 | DRUG RELEASE MEANS FROM LIPOSOMES AND METHOD FOR EVALUATING RELEASABILITY - Drug release means from liposomes and a method for evaluating drug releasability of liposome preparations, which are useful for the quality control of a liposome preparation, are simple, accurate and excellent in reproducibility and are able to achieve in vivo/in vitro correlation (IVIVC), are provided. The drug release means from liposomes by causing the shift of chemical equilibrium in the inside of the liposome and the method for evaluating drug releasability by quantitatively determining the drug released to the outside of the liposome. | 09-15-2011 |
| 20110236982 | ANALYSIS OF MASS SPECTRAL DATA IN THE QUIET ZONES - Embodiments of this invention relate to the analysis of mass spectral data in the quiet zones. | 09-29-2011 |
| 20110244584 | APPARATUS AND METHODS FOR DIAGNOSING RENAL DISORDERS - The present invention provides a system comprising an array of chemically sensitive sensors based on coated single walled carbon nanotubes, for measuring volatile organic compounds indicative of renal failure. Methods of breath analysis for diagnosing chronic, acute and end-stage renal failure are disclosed. | 10-06-2011 |
| 20120003745 | METHOD FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, PROGRAM FOR IMPLEMENTING THE SAME, AND APPARATUS FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN - When assessing the start time of the limulus reaction between biogenous biologically active substances and LAL and using the reaction start time to determine the concentration of the biogenous biologically active substances, in order to exclude the influence of progressive changes which occur regardless of the conditions of the limulus reaction, the strength of transmitted light or scattered light in the liquid mixture of the measurement sample and LAL is detected, the variation (delta) in the transmittance or number of gel particles is acquired at set intervals, and the time when the variation (delta) crosses a threshold value is taken as the reaction start time. Furthermore, the time intervals when acquiring the abovementioned delta are not uniform, and either change over time from the start of measurement as defined by a time function, or multiple sequences with differing time intervals are prepared in advance. | 01-05-2012 |
| 20120015441 | APPARATUS FOR MEASURING CHOLESTEROL AND METHOD THEREOF - A microfluidic device and method for measuring a level of cholesterol therewith are provided. The cholesterol measurement apparatus includes a microfluidic device including a plurality of chambers and at least one channel through which the plurality of chambers are interconnected. The plurality of chambers include a reaction chamber which contains a capture binder, a buffer chamber which contains an elution buffer and is connected to the reaction chamber, and at least one detection chamber which contains a cholesterol measurement reagent and is connected to the reaction chamber. | 01-19-2012 |
| 20120088305 | MASS SPECTROMETRIC DETERMINATION OF EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID - The invention relates to the detection of DHA and EPA. In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry. | 04-12-2012 |
| 20120238027 | Methods and Systems for Determining the Presence or Amount of Testosterone in a Sample - Disclosed are methods and systems for the analysis of testosterone in a sample using supported liquid extraction and liquid chromatography-mass spectrometry. | 09-20-2012 |
| 20120238028 | Means and Methods for Diagnosing Multiple Sclerosis - The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing multiple sclerosis in a subject, a method for identifying whether a subject is in need for a therapy of multiple sclerosis or a method for determining whether a multiple sclerosis therapy is successful. Moreover, contributed is a method for diagnosing or predicting the risk of an active status of multiple sclerosis in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. | 09-20-2012 |
| 20120270327 | Methods and Systems for Determining the Presence or Amount of Delta 5 Steroid Compounds in a Sample - Disclosed are methods and systems for the analysis of delta 5 steroid compounds in a sample using supported liquid extraction and liquid chromatography/mass spectrometry. | 10-25-2012 |
| 20120295361 | MEASURING LEVELS OF A METABOLITE - Described herein are methods for determining an amount of an analyte in a test sample. The methods involve preparing a calibration curve using standard samples containing an isotopically-labeled standard in a biological matrix. | 11-22-2012 |
| 20120329161 | METHOD FOR ASSESSMENT OF HEPATIC FUNCTION AND PORTAL BLOOD FLOW - A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease. | 12-27-2012 |
| 20130023054 | LIPID BIOMARKERS FOR STABLE AND UNSTABLE HEART DISEASE - The present invention relates generally to the field of diagnostic and prognostic assays for heart disease. More particular, the present invention provides an assay for diagnosing the presence or extent of development of heart disease or its classification or state thereof. The assay of the present invention is also useful in the stratification of a subject with respect to a risk of developing heart disease. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic and reporting system. | 01-24-2013 |
| 20130157374 | METHOD FOR QUANTIFYING THE AMOUNT OF CHOLESTEROL IN HIGH-DENSITY LIPOPROTEIN 3 - A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein a surfactant that reacts with lipoproteins other than high-density lipoprotein 3 is reacted with a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample. | 06-20-2013 |
| 20130177990 | METHODS OF DETERMINING EFFICACY OF CYCLODEXTRIN THERAPY - Disclosed are methods for determining efficacy of a cyclodextrin therapy in a subject afflicted with a disorder involving oxysterol accumulation. These methods comprise: obtaining a first body fluid sample from the subject prior to cyclodextrin administration; administering cyclodextrin; obtaining at least one second body fluid sample after the cyclodextrin administration; subjecting the body fluid samples to chromatography-mass spectroscopy analysis to determine concentration of 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol; and determining magnitude of difference between the 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol concentration of the body fluid samples, whereby an increase or stabilization of 24-hydroxycholesterol concentration, or a reduction of cholestane-3β,5α,6β-triol concentration in the at least one second sample compared to the first sample, indicates efficacy of the cyclodextrin therapy. | 07-11-2013 |
| 20130203176 | DETECTION METHOD - The object of the present invention is to provide a biomarker which is highly correlated to the conventional biomarkers of metabolic syndrome or life-style related disease in a wide range of subjects to be tested, including subjects of special health check-up aged between 40 and 74, or an advantageous method for detecting metabolic syndrome or life-style related disease. The object can be solved by a method for detecting metabolic syndrome or life-style related disease characterized by comprising the step of measuring the concentration of choline plasmalogen in a sample to be tested. | 08-08-2013 |
| 20130244333 | BIOLOGICAL MARKERS FOR LONGEVITY AND DISEASES AND USES THEREOF - This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the −641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease. | 09-19-2013 |
| 20130280812 | APPARATUS AND METHOD FOR THERMAL ASSISTED DESORPTION IONIZATION SYSTEMS - The present invention is directed to a method and device to desorb an analyte using heat to allow desorption of the analyte molecules, where the desorbed analyte molecules are ionized with ambient temperature ionizing species. In various embodiments of the invention a current is passed through a mesh upon which the analyte molecules are present. The current heats the mesh and results in desorption of the analyte molecules which then interact with gas phase metastable neutral molecules or atoms to form analyte ions characteristic of the analyte molecules. | 10-24-2013 |
| 20130295678 | SYSTEMS AND METHODS FOR NON-FASTING LDL CHOLESTEROL ASSAYS - In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including POE-POP-POE block copolymer, a surfactant, and a reflectivity changing reactant, the POE-POP-POE block copolymers solubilizing essentially only non-LDL cholesterol analytes, the non-LDL cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample. | 11-07-2013 |
| 20130316462 | RAPID AND HIGH-THROUGHPUT ANALYSIS OF STEROLS/STANOLS OR DERIVATIVES THEREOF - This invention relates to a rapid, high-throughput process for analyzing one or more sterols/stanols or derivatives thereof in a plurality of samples. The method comprises the steps of introducing a plurality of samples containing one or more sterols/stanols or derivatives thereof into individual vessels in a multi-vessel plate; cleaving the one or more sterols/stanols or derivatives thereof of each sample in the multi-vessel plate to form free sterols/stanols; extracting the free sterols/stanols of each sample by solid phase extraction; and detecting the level of the extracted free sterols/stanols in each sample by liquid chromatography tandem mass spectrometry. In this process, the free sterols/stanols do not undergo an additional derivitization step of adding a functional group to the free sterols/stanols prior to the detecting step. | 11-28-2013 |
| 20130323849 | Selective Detection and Analysis of Small Molecules - The invention relates to a material, process and method for the selective analysis of small molecules. Particularly the invention provides a material and a technique for the analysis of small molecules excluding other large molecular weight (MW) analytes. The process involves selective detection of low molecular weight molecules from a sample comprising the steps of placing said sample with SBA-15 particles; and subjecting the same to desorption ionization mass spectrometry, wherein low molecular weight molecules are selectively detected over the higher molecular weight molecules. A kit for the selective analysis of small molecules is also provided. | 12-05-2013 |
| 20140024122 | ANALYTE DETECTION USING LIQUID CRYSTALS - Devices and methods for using changes in the defects in micrometer sized dispersed liquid crystal domains to detect or quantify analytes in a test sample, including endotoxin lipopolysaccharide (LPS), are disclosed. The dispersed liquid crystal microdomains are exposed to the test sample, and any changes in the number of defects in the liquid crystal microdomains are detected by detecting changes in the anchoring configuration of the microdomains. Such changes in anchoring configuration indicate the presence of analyte in the test sample. | 01-23-2014 |
| 20140186964 | MEANS AND METHODS FOR ASSESSING INCREASED PEROXISOMAL PROLIFERATION - The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject. | 07-03-2014 |
| 20140273250 | METHODS FOR THE SELECTIVE DETECTION OF ALKYNE-PRESENTING MOLECULES AND RELATED COMPOSITIONS AND SYSTEMS - Provided herein are methods for selectively detecting an alkyne-presenting molecule in a sample and related detection reagents, compositions, methods and systems. | 09-18-2014 |
| 20140302611 | ASSAY CARTRIDGE - An assay cartridge has a base member ( | 10-09-2014 |
| 20140342460 | FREE FATTY ACID PARTICLE DISPERSION SOLUTION AND PREPARATION METHOD THEREOF - Provided is a preparation method of a free fatty acid particle dispersion solution, the preparation method including: a) dissolving fatty acid in a solvent to prepare a fatty acid solution; and b) injecting the fatty acid solution in a non-solvent having miscibility with the solvent to prepare a free fatty acid particle dispersion solution. | 11-20-2014 |
| 20150044774 | METHOD FOR QUANTIFYING CHOLESTEROL IN HIGH DENSITY LIPOPROTEIN 3 - Disclosed is the provision of a method for quantifying HDL3 in a test sample without requiring a laborious operation. The method for quantifying cholesterol in high-density lipoprotein 3 comprises allowing a surfactant(s) which specifically react(s) with a high-density lipoprotein 3 to react with a test sample and quantifying cholesterol, and the surfactant(s) is(are) at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ether and polyoxyethylene styrenated phenyl ether. | 02-12-2015 |
| 20150044775 | Measurement Method and Device, For Determining Degree of Engine Oil Dilution by FAME - For checking engine oil, especially containing rate of FAME (Fatty Acid Methyl Ester), we provide a measuring device including a cylindrical and upright analysis vessel having a reading scale with which a surface boundary is measured. In the vessel, the engine oil is mixed with reagents including alcohol(s) and a demulsifier. And the decreased volume is checked as volume of the FAME contained in the engine oil. | 02-12-2015 |
| 20150056708 | METHODS FOR DETECTING ESTRONE BY MASS SPECTROMETRY - Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample. | 02-26-2015 |
| 20150147817 | PC-O 44:4 - A BIOMARKER FOR VISCERAL ADIPOSITY - The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject. | 05-28-2015 |
| 20150316507 | METHODS FOR ANALYSIS OF ISOMERIC LIPIDS - A method for analyzing a sample that contains a plurality of lipid isomers is described that involves forming one or more lipid metal ion adducts and transporting the one or more lipid metal ion adducts through a Mix of POPC+OPPC differential mobility spectrometer to cause separation of the one or more lipid metal ion adducts from each other. The lipid isomers can be chosen, for example, from fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, sterol lipids, and prenol lipids. Particular examples include phosphatidylcholine regioisomers such as 1-palmatoyl-2-oleoyl-sn-phosphatidylcholine (POPC) and 1-oleoyl-2-palmatoyl-sn-phosphatidylcholine and triacylglycerols containg palmetic and oleic acid groups. The metal chosen can include a cationization reagent that contains sodium, potassium, silver or lithium. | 11-05-2015 |
| 20150331001 | METHODS AND APPARATUS FOR THE ANALYSIS OF FATTY ACIDS - Exemplary embodiments of the present disclosure relate to CO | 11-19-2015 |
| 20160025606 | METHOD AND APPARATUS FOR THE EXTRACTION OF VITAMIN D METABOLITES FROM HUMAN PLASMA - This invention relates to a method and apparatus or kit for extracting major metabolites of vitamin D from human plasma or serum. More particularly, the invention provides for the extraction from human plasma or serum samples comprising vitamin D metabolites such as 1,25-dihydroxy vitamin D3, 25-hydroxy vitamin D2, and D3 from protein binding, removal of protein and phospholipids, and isolation of the metabolites using a combination of ion-exchange and Lewis acid mechanisms without the requirement to acidify the samples. The method and apparatus of the invention comprise a cartridge or plurality of cartridges comprising at least one protein crash frit, a strong cation exchanged sorbent, and an acidified alumina sorbent to provide higher recoveries of vitamin D metabolites than existing phospholipid depletion plate techniques. Accurately quantifying 1,25-dihydroxy vitamin D3 is useful in differential diagnosis of vitamin D-related diseases and for monitoring vitamin D therapy in patients with chronic renal disease. | 01-28-2016 |
| 20160047789 | DETECTION OF TRACE POLAR COMPOUNDS BY OPTICAL SENSORS - A method of detecting a polar compound in a sample, such as a fuel sample. The method including: contacting the sample with a solvatochromic compound, wherein the solvatochromic compound undergoes a shift in spectral absorbance when in contact with polar compounds in the sample; and detecting a change in spectral absorbance of the solvatochromic compound, thereby detecting polar compounds in the sample. | 02-18-2016 |
| 20160047799 | DETECTION OF COMPOUNDS IN A DRIED FLUID SPOT BY DIRECT MALDI/MS - It is provided a method for detection and/or quantification of at least one molecule presents in blood by a MALDI-MS analysis of a dried fluid spot without the presence of any digestion step or liquid extraction step, which permits to further analyse the physical distribution of at least one molecule within a dried fluid spot. | 02-18-2016 |
| 20160047830 | LYSOPHOSPHATIDIC ACID DETECTION - Embodiments of methods and compounds for isolating and detecting lysophosphatidic acids (LPAs) are disclosed. Kits for performing the methods also are disclosed. LPAs are isolated from biological samples by liquid-liquid extraction followed by solid phase extraction. LPA species may be separated by HPLC, and the separated species may be identified and quantified. Also disclosed are embodiments of compounds capable of universally detecting a plurality of LPA species with substantially equivalent sensitivity. Embodiments of the disclosed compounds are useful for determination of total LPA concentration in a sample comprising a plurality of LPA species without separation of individual LPA species. | 02-18-2016 |
| 20160109471 | LIPOPROTEIN PARTICLE NUMBER FROM MEASUREMENTS OF LIPOPROTEIN PARTICLE PHOSPHOLIPID CONCENTRATION IN LIPOPROTEIN PARTICLE MEMBRANE BILAYER - This application describes a method for measuring the molar concentrations of lipoprotein particles and lipoprotein subclass particles in bodily fluid by Multipixel Capillary Isotachophoresis Laser Induced Fluorescence (MPCE-ITP-LIF) and compositional analysis of spherical lipoprotein particles. The ability to measure several kinds of lipoproteins and particles in one unified system provides a useful diagnostic tool for predicting the risk of developing metabolic diseases such as cardiovascular disease and cardiodiabetes. | 04-21-2016 |
| 20160131642 | GRATING PATTERN ELEMENT, TARGET MATERIAL MEASURING APPARATUS, AND TARGET MATERIAL MEASURING METHOD - A grating pattern element includes peaks which are periodically arranged and valleys provided between the peaks, and at least one of the peaks and at least one of the valleys includes an adsorbing material on a surface thereof which adsorbs a target material. | 05-12-2016 |
| 20160153953 | Water Testing | 06-02-2016 |
| 20160195559 | Method For Detecting Risk Factor For Metabolic Syndrome or Hyperferritinemia | 07-07-2016 |
| 20180024150 | BIOMARKER OF DEMENTIA WITH LEWY BODIES | 01-25-2018 |
| 20190145990 | Methods and Systems to Detect and Quantify the Amount of LP-X and Other Abnormal Lipoproteins in a Biosample Using NMR Spectroscopy | 05-16-2019 |
